XPRIZE Healthspan is a seven-year competition designed to push aging research beyond incremental improvements. Participating teams are developing and testing interventions intended to restore muscle, cognitive, and immune performance in adults between 50 and 90 years of age. The competition defines success as producing measurable improvements equivalent to at least 10 years of healthier function—and potentially as much as 20 years—within one year or less of treatment. The goal is not simply to increase lifespan, but to delay or reverse functional decline while people remain active and independent.

The NYC-Vita team is conducting a clinical trial that combines lifestyle and pharmaceutical interventions to examine whether immune-system performance can be improved during aging. The study reflects a growing scientific consensus that aging is not governed by a single mechanism. Instead, it emerges from interconnected changes involving chronic inflammation, metabolic dysfunction, impaired tissue repair, altered immune-cell behavior, vascular damage, and declining neurological resilience. By measuring these processes together, the researchers hope to determine whether targeted interventions can produce broad improvements in healthspan rather than isolated changes in one organ.

A central scientific focus of the program is the aging immune system, a process known as immunosenescence. With age, immune cells may become less responsive to new infections and vaccines, while other immune populations can remain persistently activated and promote low-grade inflammation. This chronic inflammatory state, sometimes called inflammaging, has been associated with cardiovascular disease, neurodegeneration, frailty, metabolic disorders, and reduced ability to recover from illness. NYC-Vita is designed to investigate whether pharmaceutical and behavioral strategies can shift the immune system toward a more balanced and effective state.

The Mount Sinai effort brings together specialists in immunology, neuroscience, metabolism, medical imaging, wearable technology, and clinical investigation. Miriam Merad, MD, PhD, leads the NYC-Vita team and is internationally recognized for her research on macrophages, immune cells that regulate inflammation, tissue repair, and responses to disease. The team also includes Zahi Fayad, PhD, whose work uses advanced imaging and wearable technologies to study biological and lifestyle stressors; Fanny Elahi, MD, PhD, an expert in neurodegeneration and brain health; Thomas Marron, MD, PhD, principal investigator of the NYC-Vita clinical trial; and Ryan W. Walker, PhD, MS, whose research examines metabolic and nutritional influences on healthy aging.

For the study, the researchers are expected to evaluate healthspan using multiple biological and functional measures rather than relying on chronological age alone. Such assessments can include immune-cell profiles, inflammatory markers, metabolic measurements, neurocognitive testing, physical-performance data, and imaging-based indicators of tissue health. Wearable devices may provide continuous information about activity, sleep, heart-rate patterns, and other behavioral signals. Combining these data streams could help researchers identify whether an intervention produces a coordinated improvement across systems or merely changes a laboratory measurement without meaningful benefits in daily life.

“Advancing to the finals of this highly competitive global initiative reflects the exceptional scientific foundation we have built at Mount Sinai and the strength of our collaborative research enterprise,” said Eric J. Nestler, MD, PhD, Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai and Executive Vice President of the Mount Sinai Health System. He said the collaboration across immunology, neuroscience, metabolism, imaging, and clinical research could help redefine how healthy aging is understood and promoted.

Merad said the team’s selection as a finalist recognizes both the promise of its scientific strategy and the work of its multidisciplinary researchers. The $1 million award will support the continued development of NYC-Vita and help accelerate investigations into interventions that may preserve physical strength, independence, and quality of life. The program is part of Mount Sinai’s broader Healthspan Program, which links biomedical research with clinical care and aims to translate discoveries about aging into practical approaches for preventing or delaying age-related disease.

XPRIZE announced 20 finalist teams at an awards ceremony in Salt Lake City. Ten of those teams, including Mount Sinai, were selected as Milestone 2 Awardees and will share $10 million in direct milestone funding, with each receiving $1 million. Awardees will also gain access to clinical testing resources intended to speed the evaluation of their therapeutic approaches. The finalists represent the United States, South Korea, Japan, and China, underscoring the international competition surrounding efforts to alter the biology of aging. The contest is scheduled to culminate in 2030, when XPRIZE plans to award a grand prize of up to $81 million. Mount Sinai leaders said the team will continue the NYC-Vita trial while seeking additional collaborators and philanthropic support to expand the research and determine whether improvements in immune health can translate into longer, healthier lives.

Subject of Research: Healthy aging, immune-system function, immunosenescence, inflammaging, and interventions designed to extend healthspan.

Article Title: Mount Sinai Team Advances to XPRIZE Healthspan Finals With Immune-Aging Clinical Trial

News Publication Date: August 11, 2026

Web References:
https://www.mountsinai.org/about/healthspan/research
https://profiles.mountsinai.org/miriam-merad
https://profiles.mountsinai.org/zahi-a-fayad
https://profiles.mountsinai.org/fanny-m-elahi
https://profiles.mountsinai.org/thomas-u-marron
https://profiles.icahn.mssm.edu/ryan-w-walker
https://www.mountsinai.org/about/executive-leadership/nestler
https://www.mountsinai.org/about/executive-leadership/brendan-carr

References: XPRIZE Healthspan competition announcement; Icahn School of Medicine at Mount Sinai NYC-Vita clinical trial and Healthspan Program information.

Keywords: healthy aging, healthspan, XPRIZE Healthspan, NYC-Vita, immune aging, immunosenescence, inflammaging, macrophages, clinical trial, Mount Sinai, longevity research, age-related disease, medical imaging, wearable technology, neuroscience, metabolism

ALS, a relentless and fatal neurodegenerative disorder characterized by the progressive degeneration of motor neurons, poses significant challenges to early diagnosis, hampering timely intervention efforts. The typical diagnostic window averages between 10 to 16 months from the onset of clinical symptoms in the United States, often delaying crucial support and treatment. Traditional diagnostic modalities rely on invasive fluid biopsies and sophisticated neuroimaging techniques, which are not only costly but also logistically cumbersome for widespread clinical deployment. This recent research shifts the diagnostic frontier to a seemingly simple biological substrate—human hair—shedding new light on elemental biodynamics as a biomarker for ALS.

At the core of this revolutionary study lies the utilization of laser ablation-inductively coupled plasma-mass spectrometry (LA-ICP-MS), an analytical method known for its ability to provide high-resolution temporal and spatial data on elemental composition. By directing a focused laser beam to vaporize minuscule segments of a hair fiber, the technique allows for the detection and quantification of trace elements and isotopes with exceptional sensitivity. In this study, hair strands from 391 participants, comprising 295 ALS-diagnosed patients and 96 healthy controls, underwent rigorous LA-ICP-MS analysis. Each strand yielded a wealth of data, capturing up to 800 discrete time points corresponding to elemental fluctuations occurring at two to four-hour intervals throughout hair growth.

The researchers quantified seventeen biologically relevant elements, including copper, zinc, magnesium, and lead, constructing intricate temporal profiles of elemental abundance. Employing sophisticated information theory-based computational frameworks, they dissected these patterns to unveil systemic dysregulation associated with ALS. Notably, the study revealed that copper, a trace element integral to numerous enzymatic processes and neuronal function, exhibited markedly diminished synchrony within elemental networks in ALS patients compared to healthy individuals. This loss of coordinated copper dynamics suggests a profound disruption in systemic copper metabolism, a pathological hallmark with significant implications for ALS pathogenesis.

Further stratification by sex unearthed intriguing sex-specific elemental imbalances: male ALS patients exhibited pronounced decrements in copper-zinc network coherence, whereas female patients demonstrated marked disturbances in chromium-nickel interactions. These differential patterns underscore the complexity of ALS and hint at divergent biochemical pathways that might underpin disease manifestation across genders. Such nuanced insights open avenues for precision diagnostics and tailored therapeutic strategies inspired by gender-specific biomarkers.

The implications of this research are profound and multifaceted. By harnessing hair strands as bioarchives that chronicle elemental fluctuations over time, clinicians could soon access a lightning-fast, painless diagnostic tool that circumvents the limitations of current practices. Unlike fluid biopsies or neuroimaging, hair sampling is straightforward, low-cost, and non-invasive, lending itself to broad implementation in diverse healthcare settings, including resource-limited environments.

Moreover, the temporal granularity of elemental data embedded in hair strands offers a dynamic window into the biodynamics of biometals implicated in ALS. This temporal dimension enriches diagnostic accuracy and provides a substrate for monitoring disease progression or response to therapy, potentially transforming patient care paradigms. As ALS remains incurable, early diagnosis enabled by such novel biomarkers is paramount in initiating symptomatic treatments, personalized nutritional plans, and multidisciplinary care interventions that collectively enhance life quality and survival outcomes.

Despite not yet yielding a validated diagnostic test, the study represents an essential proof-of-concept milestone. It demonstrates that the analysis of elemental biodynamics in hair is not merely theoretical but practically achievable, with measurable and reproducible differences between ALS patients and controls. This validation paves the way for expansive clinical trials to refine and standardize hair-based diagnostic platforms, which may one day integrate seamlessly into routine neurological assessments.

The research team, led by Manish Arora, BDS, MPH, PhD, and Vishal Midya, PhD, underscores the transformative promise of their method. Dr. Arora highlights the capacity of hair to serve as a peripheral mirror of systemic elemental balance, remarking that their approach “has the potential to transform how we diagnose ALS, making it faster, easier, and more accessible for patients.” Dr. Midya adds that these findings provide a foundation for scalable diagnostics that could be deployed at a population level, an advance critically needed in the fight against a disease as devastating as ALS.

This landmark investigation was conducted in collaboration with Linus Biotechnology, Inc., Dartmouth University, and Columbia University, complemented by funding from the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC). These partnerships highlight the interdisciplinary and multi-institutional nature of cutting-edge efforts tackling neurodegenerative diseases.

As the research community awaits further validation studies and technological refinement, the potential of hair-strand elemental biodynamics as a diagnostic medium represents a beacon of hope for the ALS patient community. By shortening diagnostic delays, this innovation could enable earlier therapeutic engagement, improve management strategies, and ultimately contribute to better clinical outcomes.

Beyond ALS, this investigative framework may extend to other neurological disorders characterized by elemental imbalances, opening a new frontier in biomarker discovery and personalized medicine. The integration of advanced mass spectrometry with intelligent data analytics applied to an everyday biological sample exemplifies the ingenuity propelling modern biomedical research.

In summation, the compelling evidence presented by the Mount Sinai team illustrates that a single strand of hair is far more than keratinized tissue—it is a dynamic repository encoding systemic biochemical rhythms. Its analysis through state-of-the-art spectrometric technology has forged a novel pathway for ALS diagnostics, heralding a future where neurodegenerative diseases may be detected with greater speed, accuracy, and accessibility than ever before.

Subject of Research: Human tissue samples
Article Title: Dysregulation of hair-strand-based elemental biodynamics in amyotrophic lateral sclerosis
News Publication Date: September 4, 2025
Image Credits: Mount Sinai Health System
Keywords: Amyotrophic lateral sclerosis, ALS, Hair analysis, Biomarkers, Elemental biodynamics, Copper metabolism, Neurodegenerative diseases, Laser ablation inductively coupled plasma mass spectrometry, LA-ICP-MS, Non-invasive diagnostics, Neurological disorders